Precision oncology company Race Oncology (ASX: RAC) is looking to raise capital to enable the execution of its expanded business strategy and to progress the clinical program of its anti-cancer drug Zantrene following a recent breakthrough discovery. The company has opened a share purchase plan to raise up to $29.7 million to fund a number […]
The post Race Oncology seeks cash to advance anti-cancer and heart protection drug appeared first on Small Caps.
from Small Caps https://ift.tt/3luXu5D
Post a Comment